The results showed that there were no significant differences of circulating RBP4 levels in the following comparisons: (1) NAFLD patients vs controls (SMD: 0.08; 95% CI: −0.21, 0.38; P = 0.568) (Fig. 2a); (2) NASH patients vs controls (SMD: −0.49; 95% CI: −1.09, 0.12; P = 0.116) (Fig. 2b); (3) SS patients vs controls (SMD: −0.72; 95% CI: −1.64, 0.20; P = 0.125) (Fig. 2c) and (4) NASH vs SS patients (SMD: −0.04; 95% CI: −0.32, 0.24; P = 0.791) (Fig. 2d). This evidence concerns the gene RBP4 and metabolic dysfunction-associated steatohepatitis.